N
VERV

Nuveen’s Verve Therapeutics VERV Stock Holding History

Nuveen’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,611,913
Closed -$18.1M – 3316
2025
Q2 		$18.1M Buy
1,611,913
+287,244
+22% +$1.64M 0.01% 1166
2025
Q1 		$6.05M Buy
1,324,669
+8,898
+0.7% +$59.6K ﹤0.01% 1825
2024
Q4 		$7.42M Sell
1,315,771
-355,953
-21% -$2.01M ﹤0.01% 1762
2024
Q3 		$8.09M Buy
1,671,724
+861,227
+106% +$5M ﹤0.01% 1741
2024
Q2 		$3.96M Sell
810,497
-64,722
-7% -$407K ﹤0.01% 2069
2024
Q1 		$11.6M Buy
875,219
+416,971
+91% +$5.53M ﹤0.01% 1507
2023
Q4 		$6.39M Buy
458,248
+279,604
+157% +$3.47M ﹤0.01% 1841
2023
Q3 		$2.37M Buy
178,644
+2,740
+2% +$44.1K ﹤0.01% 2224
2023
Q2 		$3.3M Buy
175,904
+15,180
+9% +$253K ﹤0.01% 2114
2023
Q1 		$2.32M Sell
160,724
-27,750
-15% -$543K ﹤0.01% 2272
2022
Q4 		$3.65M Sell
188,474
-109,910
-37% -$2.91M ﹤0.01% 2094
2022
Q3 		$10.3M Buy
298,384
+148,964
+100% +$4.75M ﹤0.01% 1457
2022
Q2 		$2.28M Buy
149,420
+16,879
+13% +$261K ﹤0.01% 2371
2022
Q1 		$2.91M Buy
132,541
+76,644
+137% +$2.19M ﹤0.01% 2339
2021
Q4 		$1.83M Sell
55,897
-4,100
-7% -$172K ﹤0.01% 2606
2021
Q3 		$2.82M Buy
+59,997
New +$3.53M ﹤0.01% 2514

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Nuveen's VERV Position: Q3 2025 in Review

Nuveen sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,611,913 shares — an estimated $18.1M sold.

Nuveen first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $18.1M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Nuveen reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nuveen sold 1,611,913 Verve Therapeutics shares in Q3 2025, an estimated $18.1M.
  • Nuveen first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Nuveen's Verve Therapeutics position peaked at $18.1M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.